Spinraza

E24879

antisense oligonucleotide biologic medicinal product medication orphan drug prescription drug

Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.

Try in SPARQL Jump to: Surface forms Statements Referenced by

All labels observed (3)

Label	Occurrences
nusinersen	5
Spinraza canonical	4
SMN2	1

Statements (49)

Predicate	Object
instanceOf	antisense oligonucleotide ⓘ biologic medicinal product ⓘ medication ⓘ orphan drug ⓘ prescription drug ⓘ
approvedBy	European Medicines Agency ⓘ Food and Drug Administration ⓘ surface form: U.S. Food and Drug Administration
developedBy	Biogen ⓘ Ionis Pharmaceuticals ⓘ
hasActiveIngredient	Spinraza self-linksurface differs ⓘ surface form: nusinersen
hasAdministrationSite	cerebrospinal fluid ⓘ
hasATCCode	M09AX07 ⓘ
hasBrandOwner	Biogen ⓘ
hasCommonAdverseEffect	back pain ⓘ constipation ⓘ headache ⓘ nausea ⓘ respiratory infection ⓘ
hasDosageForm	solution for injection ⓘ
hasGenericName	Spinraza self-linksurface differs ⓘ surface form: nusinersen
hasInternationalNonproprietaryName	Spinraza self-linksurface differs ⓘ surface form: nusinersen
hasLoadingDoseRegimen	four loading doses over approximately two months ⓘ
hasMaintenanceDoseRegimen	one dose every four months ⓘ
hasPregnancyCategory	not assigned; use only if potential benefit justifies potential risk ⓘ
hasSeriousAdverseEffect	coagulation abnormalities ⓘ renal toxicity ⓘ thrombocytopenia ⓘ
hasTherapeuticArea	neurology ⓘ rare diseases ⓘ
increasesProductionOf	survival motor neuron protein ⓘ surface form: SMN protein survival motor neuron protein ⓘ
indicatedFor	adult patients with spinal muscular atrophy ⓘ pediatric patients with spinal muscular atrophy ⓘ
isAdministeredBy	healthcare professional ⓘ
isFirstDrugApprovedFor	spinal muscular atrophy ⓘ
isUsedAs	disease-modifying therapy for spinal muscular atrophy ⓘ
legalStatusInEuropeanUnion	prescription only ⓘ
legalStatusInUnitedStates	prescription only ⓘ
mechanismOfAction	antisense oligonucleotide that modulates SMN2 pre-mRNA splicing ⓘ
modifiesGeneExpression	SMN2 ⓘ
regulatoryApprovalYear	2016 ⓘ
requiresMonitoringOf	coagulation parameters ⓘ platelet count ⓘ renal function ⓘ
routeOfAdministration	intrathecal ⓘ lumbar puncture ⓘ
targetsGene	Spinraza self-linksurface differs ⓘ surface form: SMN2
treats	5q spinal muscular atrophy ⓘ spinal muscular atrophy ⓘ

Referenced by (10)

Full triples — surface form annotated when it differs from this entity's canonical label.

Biogen → hasProduct → Spinraza ⓘ

Biogen → hasNotableDrug → Spinraza ⓘ

Spinraza → hasGenericName → Spinraza self-linksurface differs ⓘ